Viewing Study NCT02474069


Ignite Creation Date: 2025-12-24 @ 11:13 PM
Ignite Modification Date: 2026-01-11 @ 4:02 AM
Study NCT ID: NCT02474069
Status: COMPLETED
Last Update Posted: 2019-07-05
First Post: 2015-02-26
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
Sponsor: Novartis Pharmaceuticals
Organization: